Erasca Stock

erasca.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $64MM

Erasca is a biotechnology company committed to solving oncology’s hardest problems.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Erasca before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value

Powered by Forge Data

Access valuation and stock price for companies like Erasca before its IPO.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Erasca’s stock FAQs


Can you buy Erasca’s stock?

You can no longer buy Erasca’s stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.

Can you sell Erasca’s stock?

You can no longer sell stock of Erasca on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.

What is Erasca’s stock price?

The stock price of Erasca is $1.78 as of 1/18/24.

What is Erasca’s stock ticker symbol?

The ticker symbol of Erasca is ERAS.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.


Management Team

Gary Yeung
Chief Business Officer
Jonathan Lim MD
Founder and Executive Chairman

Board Members

James Bristol Ph.D
Jonathan Lim MD
Pratik Multani MD
Alexander Casdin


Erasca Brings In $36M More For Series B For Cancer Treatments

Erasca will use the funding to drive corporate development efforts and further advance the company’s in-house drug discovery pipeline.

San Diego’s Erasca Lands $200M In Series B Round 

San Diego-based cancer treatment startup Erasca raised $200 million in a new round of funding, the company announced Monday.

Erasca Raises $200M in Series B Financing | FinSMEs

Erasca, a San Diego, CA-based develper of oncology programs, completed a $200m Series B financing round co-led by Arch Venture Partners and Cormorant Asset Management
Updated on: Jun 24, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.